tag drug-affordability 
World of DTC Marketing
JULY 20, 2022
A new analysis released Wednesday by Patients for Affordable Drugs estimates that pharmaceutical companies in the U.S. have raised drug prices 1,186 times so far this year. Patients for Affordable Drugs found that between June 24 and July 5, pharmaceutical companies increased prices for 133 products.
Drug Discovery World
DECEMBER 20, 2022
World’s most expensive drug. million, making it the world’s most expensive drug. . Concerns about the high price tag have been raised in an article in Nature, particularly whether it will be affordable for low to middle-income countries. . A one-time treatment with etranacogene dezaparvovec costs US$3.5
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JULY 13, 2023
In modeling exercises, optimal implementation of these therapies, such as an ARNI, a beta blocker, an MRA, and an SGLT2 inhibitor, compared to conventional therapy (an ACEi or ARB plus a beta blocker) is estimated to afford more than 6 years of survival in a typical 55-year-old patient.
XTalks
JULY 12, 2021
The US Food and Drug Administration’s (FDA) recent approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) was met with a lot of backlash, prompting the health agency to narrow its recommendation of the drug for mild forms of the disease. All of this for a drug that has shown questionable clinical benefits, critics say.
XTalks
APRIL 18, 2024
Roche has received Breakthrough Device designation from the US Food and Drug Administration (FDA) for its Elecsys pTau217 early Alzheimer’s blood test. To help advise on new Alzheimer’s drug submissions, the FDA issued draft guidance on developing drugs for the treatment of early Alzheimer’s disease last month.
pharmaphorum
JUNE 2, 2022
R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. Evaluate Pharma’s recent Orphan Drug Report subtitled its overview of the market ‘Niche no longer.’ It is estimated that between 3.5
pharmaphorum
JANUARY 21, 2022
Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry. By 2026, she said, more than half of all public spend on medicines in Europe will be on cancer drugs for just 2% to 3% of the patient base.
Expert insights. Personalized for you.
183 
Let's personalize your content